Product name: Picropodophyllotoxone
Synonym name:
Catalogue No.: BP4081
Cas No.: 477-48-5
Formula: C22H20O8
Mol Weight: 412.394
Botanical Source: (-)-Picropodophyllone; Picropodophyllotoxon
Physical Description:
Type of Compound: Lignans
Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
Whenever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20℃. Generally, these will be useable for up to two weeks.
The product could be supplied from milligrams to grams
Inquire for bulk scale.
For Reference Standard and R&D, Not for Human Use Directly.
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
Picropodophyllotoxone (CAS No.: 477-48-5) is a naturally occurring compound with significant biological activity, belonging to the Picropophyllotoxone family. These compounds have attracted widespread attention in recent years due to their unique structures and diverse pharmacological activities, especially their potential applications in the anti-tumor field. Dixiphyllalipotoxicone not only inhibits various tumor cells but also involves regulation of multiple key signaling pathways, demonstrating great potential as a candidate molecule for anticancer drugs.
This review aims to systematically summarize the chemical structure and physicochemical properties of Astragalusul Lipotoxicone, plant origins and extraction methods, thoroughly explore its pharmacological activity and mechanism of action, evaluate its druggability parameters and pharmacokinetic characteristics, and look ahead to its clinical application prospects. Through comprehensive analysis of existing literature, theoretical support and scientific basis are provided for further research and development of Kuguijiulidoketone.
Bitter ghostaphylloid toxic ketone is a derivative of lidophyllin lignan, with the molecular formula C22H20O8 and a molecular weight of 412.3940. Its structural core is a polycyclic aromatic system, containing multiple hydroxyl and ketone functional groups, giving it unique chemical properties. The LogP value of Kuguijiulitoxin is 2.2585, indicating moderate lipid solubility, which facilitates cell membrane penetration and distribution in vivo. Its polar surface area (TPSA) is 89.52 Ų, indicating that the molecule has a certain affinity in polar environments.
Its low water solubility (0.0360 mg/mL) somewhat limits its bioavailability, but it also provides direction for improving drug formulations. Notably, Ku Guijiu Lipotoxicone has a high ability to penetrate the blood-brain barrier, suggesting its potential application value in central nervous system diseases. Additionally, the hERG channel inhibition test results were negative, indicating a low risk of cardiotoxicity, while the Ames test result was 0.0, indicating no significant genotoxicity.
Phytoxin is mainly found in plants of the Picropodophyllum family, especially the rhizomes and roots of Picropodophyllum. These plants are widely distributed in temperate and subarctic regions, and have traditionally been used in traditional Chinese medicine and folk herbal remedies, with effects such as clearing heat, detoxifying, and anti-tumor.
Common methods for extracting Astracophyllalipotoxicone include organic solvent extraction extraction, ultrasound-assisted extraction, and column chromatography separation techniques. Ethanol or methanol is generally used as the extraction solvent, followed by multi-step solvent extraction and silica gel column chromatography purification to obtain high-purity Astraphyllalidoketone. In recent years, the application of supercritical CO2 extraction technology has improved extraction efficiency and purity, while reducing the use of organic solvents, aligning with the concept of green chemistry.
The pharmacological activity of Kuguijiulipotoxicone is mainly anti-tumor, covering various tumor cell lines including breast cancer, lung cancer, colorectal cancer, ovarian cancer, and others. In vitro experiments show that Kuguijitar lipotoxicone can significantly inhibit tumor cell proliferation, induce apoptosis, and suppress cell migration and invasion capabilities.
In addition, Kuguijitalipoxin also shows certain activity in anti-inflammation, antioxidant, and immune function regulation, but related research is still in its early stages. Its antitumor activity is closely related to its regulation of multiple signaling pathways, exhibiting pharmacological characteristics of multiple targets and multiple mechanisms.
The antitumor mechanism of Kuguijulidoxone involves multiple key molecular pathways and targets, mainly including:
MCL1 and BCL2: Oligophyllone promotes programmed death of tumor cells by downregulating the expression of anti-apoptotic proteins MCL1 and BCL2, enhancing cellular sensitivity to apoptosis signals.
STAT3: This compound inhibits the phosphorylation and activation of STAT3, blocks its transcriptional activity, and weakens tumor cell proliferation and immune evasion.
MMP2: By inhibiting the expression of matrix metalloproteinase MMP2, Astragalusil Lipotoxicone effectively reduces the invasion and metastatic potential of tumor cells.
TOP1 vs. TOP2A: Bitter Acetasterone interferes with DNA topoisomerase I and II activities, hindering DNA replication and transcription, leading to tumor cell cycle stagnation and death.
HIF1A: This compound inhibits the expression of hypoxia-inducing factor HIF1A, weakens tumor cells' adaptability to hypoxic environments, and inhibits tumor angiogenesis.
MAPK1: By regulating the MAPK signaling pathway, Dixiphyllum lipidulone affects cell proliferation, differentiation, and apoptosis.
ESR1 and CYP19A1: Bitter Ghostaphyllum lipotoxicone regulates estrogen receptor ESR1 and aromatase CYP19A1, demonstrating its potential application value in hormone-dependent tumors such as breast cancer.
In summary, Ku Guijiu Lipotoxicone exerts its anti-tumor effect through multi-target synergistic action, demonstrating a complex yet effective mechanism of action.
The druggability parameters of Kuguijiullidoxone indicate that it has promising potential for drug development. A moderate molecular weight and LogP value facilitate its absorption and distribution in the body. High blood-brain barrier permeability suggests its potential for treating central nervous system tumors.
Its low water solubility may limit oral bioavailability, and improvements are needed through pharmaceutical methods such as nanocarriers, liposomes, or solid dispersions. The hERG channel was inhibited negatively and the Ames test showed no mutagenic results, indicating high safety and low risks of cardiotoxicity and genotoxicity.
Currently, pharmacokinetic research on Ku Guiju Lidoxone is relatively limited. Preliminary data indicate a long half-life and good tissue distribution in the body, but the specific metabolic pathways and excretion mechanisms still require further systematic study.
As a multi-target antitumor natural product, Kuguijiulidotoxicone has broad clinical application prospects. Its ability to regulate multiple tumor-related targets gives it potential advantages in treating various solid tumors and hematologic tumors. Especially in the treatment of drug-resistant and recurrent tumors, Dixiphyllone's lipidoxin may improve therapeutic outcomes by overcoming the resistance mechanisms of single-target drugs.
Future research should focus on optimizing the pharmacokinetics, developing dosage forms, and combining therapy strategies for Ku Guijiulidoketone to improve its bioavailability and efficacy. At the same time, based on its high blood-brain barrier permeability, exploring its application in brain tumors and neurological diseases is also of great significance.
In addition, the safety evaluation and preclinical toxicology research of Ku Guiju Lidoxin require further strengthening to lay a solid foundation for clinical trials. With the development of molecular biology and medicinal chemistry, optimizing the pharmacodynamic and pharmacokinetic properties of Astragalusulin lipotoxicone through structural modification and drug design will drive its advancement toward clinical translation.
As a natural product with multi-target antitumor activity, Kuguijiulidoxin demonstrates excellent druggability and broad application prospects due to its unique chemical structure and diverse pharmacological effects. Although research on its mechanism of action and pharmacokinetics is still incomplete, existing research provides a solid theoretical foundation for its development as an antitumor drug.
In the future, through in-depth mechanistic research, drug optimization, and preclinical evaluation, Kugjitasterone is expected to become an important candidate drug in the field of anti-tumor therapy, bringing new treatment options and hope to cancer patients.
